Unknown

Dataset Information

0

Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.


ABSTRACT: There is accumulating evidence that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Herein, to remodel tumor immune microenvironment and elicit synergistic antitumor effects, lipid-coated biodegradable hollow mesoporous silica nanoparticle (dHMLB) was constructed with co-encapsulation of all-trans retinoic acid (ATRA), doxorubicin (DOX) and interleukin-2 (IL-2) for chemo-immunotherapy. The nanoparticle-mediated combinational therapy provided a benign regulation on tumor microenvironment through activation of tumor infiltrating T lymphocytes and natural killer cells, promotion of cytokines secretion of IFN-γ and IL-12, and down-regulation of immunosuppressive myeloid-derived suppressor cells, cytokine IL-10 and TGF-β. ATRA/DOX/IL-2 co-loaded dHMLB demonstrated significant tumor growth and metastasis inhibition, and also exhibited favorable biodegradability and safety. This nanoplatform has great potential in developing a feasible strategy to remodel tumor immune microenvironment and achieve enhanced antitumor effect.

SUBMITTER: Kong M 

PROVIDER: S-EPMC5595131 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.

Kong Miao M   Tang Jiamin J   Qiao Qi Q   Wu Tingting T   Qi Yan Y   Tan Songwei S   Gao Xueqin X   Zhang Zhiping Z  

Theranostics 20170723 13


There is accumulating evidence that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Herein, to remodel tumor immune microenvironment and elicit synergistic antitumor effects, lipid-coated biodegradable hollow mesoporous silica nanoparticle (dHMLB) was constructed with co-encapsulation of all-trans retinoic acid (ATRA), doxorubicin (DOX) and interleukin-2 (IL-2) for chemo-immunotherapy. The nanoparticle-mediated combinational therapy provided a benign regul  ...[more]

Similar Datasets

| S-EPMC6008237 | biostudies-literature
| S-EPMC5551774 | biostudies-other
| S-EPMC6746239 | biostudies-literature
| S-EPMC4701626 | biostudies-literature
| S-EPMC8294168 | biostudies-literature
| S-EPMC10610727 | biostudies-literature
| S-EPMC4038837 | biostudies-literature
| S-EPMC4430331 | biostudies-other
| S-EPMC3985790 | biostudies-literature
| S-EPMC10885352 | biostudies-literature